Biogen Inc. is increasing its spending substantially in 2020 to build out commercial infrastructure to support the launch of aducanumab for Alzheimer's disease in the US, even though approval by the US Food and Drug Administration is far from guaranteed.
"We are actively preparing for the potential launch of aducanumab with an initial focus on the US," CEO Michel Vounatsos told investors during the company’s 30 January earnings conference call
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?